Timothy Schmidt, MD (@TMSchmidtMD) header
Timothy Schmidt, MD (@TMSchmidtMD) profile picture

Assistant Professor @UWCarbone. Proud @WinshipAtEmory, @uiccom, @slusom, @XavierU alum. Clinical investigator focusing on myeloma and plasma cell disorders.

Madison, WI
Joined July 2018
Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
3
54
1
112
7,193
What an honor to participate in this @HealthTree podcast! Is a bispecific antibody better than transplant for newly diagnosed myeloma patients? Even if you've had some treatment, you can consider joining the FASTER study, part of the @CoMMitTrials group. healthtree.org/myeloma/podca…
1
3
4
277
Now published in @FrontOncology! frontiersin.org/journals/onc… Please check out our work through the @BigTenCRC to characterize practice patterns among myeloma clinicians for management of myeloma bone disease (MBD). #mmsm 🧵1/x
1
5
382
The study has many limitations, including: 🚩 Small sample size 🚩 Descriptive analysis 🚩 Lack of specificity in some questions Despite these limitations, we are proud of this collaborative effort through the BTCRC, and we highlight some key focus areas for future research.
1
25
Timothy Schmidt, MD retweeted
ASH has released new Clinical Practice Guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening bone marrow disorder. The guidelines present 12 evidence-based recommendations designed to help clinicians improve diagnosis. ow.ly/OMEV50Y4S71
22
5
51
11,509
Timothy Schmidt, MD retweeted
#Myeloma Paper of the Day: American Society of Hematology (ASH) 2026 guidelines on diagnosis of light chain/AL #amyloidosis emphasizing serum & urine immunofixation, serum free light chains, and surrogate biopsies (both bone marrow and fat pad): pubmed.ncbi.nlm.nih.gov/4159…. #mmsm
2
29
83
5,837
Timothy Schmidt, MD retweeted
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0: 📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades. 🧪 Neutrophils: Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded. Stricter G4: threshold drops from <500 to <100/mm³. 🩸 Platelets (Thrombocytopenia): Wider G3: Now covers 10k–50k (previously 25k–50k). Stricter G4: threshold drops from <25k to <10k/mm³. v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria. Overall, IMO these new thresholds align better with clinical practice. #ClinicalTrials #MedEd #OncTwitter #DrugSafety
3
104
4
193
24,669